On May 15, 2025, a jury returned a verdict finding Amgen Inc. (“Amgen”) liable for antitrust violations and awarding Regeneron Pharmaceuticals, ...

Fed officials say debt downgrade complicates inflation outlook, Nvidia CEO discusses China chip ban, JPMorgan’s investor day, ...

Tess Stynes - profile from The Wall Street Journal. News, articles, biography and photos.

Tourmaline Bio disclosed results for a potential rival to a Novo Nordisk drug. Elsewhere, data emerged for a psychedelic and CRISPR Therapeutics expanded its toolkit.

Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter at the ...

First approved in 2010, RANK ligand (RANKL) inhibitor Prolia remains an important drug for Amgen. The company recorded sales of $3.25 billion for the drug last year, two thirds from the US market.